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htcense.Abstract Background: Airway inﬂammation and remodeling of extracellular matrix are impor-
tant features of asthma. Matrix metalloproteinases (MMPs) are group of enzymes expressed in
the airways with their inhibitor (tissue inhibitor of MMPs (TIMP) and they are the key responsible
for extra cellular matrix (ECM) degradation.
Objective: To clarify the role of MMP-9 and TIMP-1 in asthma exacerbation and airway remod-
eling.
Subjects and methods: The study included 3 groups, group ‘‘A’’ included 22 patients with stable
asthma group ‘‘B’’ included 18 patients during asthma exacerbation and group ‘‘C’’ of 18 healthy
volunteer served as control. All groups were matching age and sex. Levels of MMP-9 and TIMP-1
were measured in the induced sputum of the 3 groups. Serum IgE skin prick test and PEFR were
assessed.
Results: MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio increased in both A and B groups in com-
parison to control (P< 0.001). During exacerbation MMP-9 and MMP-9/TIMP-1 ratio showed
signiﬁcant increase for both but TIMP-1 did not show signiﬁcant change when compared to stable
asthmatics. There was signiﬁcant negative correlation between PEFR and MMP-9, TIMP-1 and
MMP-9/TIMP-1 ratio.
Conclusion: MMP-9 and TIMP-1 play an important role in pathophysiology of asthma exacer-
bation and airway remodeling. Clearly, a greater understanding of the pathogenesis of asthma is
critical to the development of better therapeutic modalities.
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Open access under CC BY-NC-ND license.om (G.M. Mohamed).
e Egyptian Society of Chest
g by Elsevier
of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
tp://dx.doi.org/10.1016/j.ejcdt.2012.10.020
36 G.M. Mohamed et al.Introduction
Matrix metalloproteinase (MMPs) are family of proteinases
with zinc- dependent proteolysis which play important roles
in matrix turnover [1]. They are secreted by wide range of stro-
mal and inﬂammatory cells that are capable of degrading all
components of extracellular matrix (ECM) [2]. MMPs, most
of which are expressed in the airways, cleave a number of
ECM constituents and can be broadly divided into collagenas-
es, gelatinases, stromelysin, elastinases and membrane bound
forms [3,4]. Also they play critical roles in lung organogenesis,
but their expression, for the most part, is down regulated after
generation of alveoli [3].
In particular, MMP-9 (gelatinase B) is reportedly increased
in the airways of asthmatic patients [5], are thought to be asso-
ciated with pathogenesis of airway inﬂammatory diseases [6,7].
Members of MMPs family are selectively inhibited by tissue
inhibitor of MMPs (TIMPs) [8]. Imbalance between MMPs
and TIMPs activities has been observed in different pathologic
conditions as rheumatoid arthritis, systemic sclerosis and he-
patic ﬁbrosis [9].
These data suggested that an excess of MMPs may be
responsible for structural degradation of tissue whereas an ex-
cess of TIMPs may promote excessive tissue repair and ﬁbrosis
[10].
Airway inﬂammation and remodeling are key histopatho-
logic features in bronchial asthma [11] sever inﬂammatory cell
inﬁltration into the lung tissue, airway structure changes
including epithelium desquamation and abnormal, extracellu-
lar matrix (ECM) degradation are observed in the patients
with chronic allergic airway diseases [12,13]. These structural
changes of the airways are thought to be the result from re-
peated acute inﬂammation which is recognized clinically as
acute exacerbation [14]. However, the relationship between air-
way remodeling and inﬂammation is poorly understood [13].
Recent studies have suggested that episodes of acute inﬂamma-
tion promote airway remodeling by altering the homeostasis of
ECM components [13]. It was suggested that MMPs have been
implicated in the turnover and airway remodeling of ECM.
Consequently, MMPs and TIMPs and more specially the bal-
ance between these two biological components may have a cru-
cial role in the pathophysiology of asthma exacerbation and
subsequent airway remodeling [15].
The aim of the present work is to clarify the role of MMP-9
and TIMP-1 in asthma exacerbation and airway remodeling.
Subjects and methods
This study included 40 atopic (atopy deﬁned as having history
of atopy and positive skin test) asthmatic patients (diagnosed
according to British thoracic society 1997) [16]. They were se-
lected from Allergy and Immunology outpatient clinic of Ain
Shams University Hospitals, Cairo, Egypt, in the duration
from February 2011 to July 2011.
They were divided into 3 groups
Group A
Twenty two patients with stable asthma, they were 11 females
and 11 males with mean age 34 ± 10.5 years. Their symptoms
and PEFR were stable with no changes in the treatment for at
least 1 month [17].Group B
Eighteen patients were recruited during acute exacerbation.
Theywere 9 females and 9males withmean age 33 ± 10.4 years.
Exacerbation was diagnosed according to breathlessness, audi-
ble wheezes on auscultation and morning peak expiratory ﬂow
rate (PEFR) <70% of the personal best value in the last
3 months [17,18].
Group C
Third group of 18 healthy volunteer subjects served as control
group. They were 10 females and 8 males within mean age
32.2 ± 10.3.
All groups were matching age and sex.Exclusion criteria
Patients with concomitant acute illnesses or pneumonia, pa-
tients receiving corticosteroids during the last month and pa-
tients with other medical diseases were excluded from the
study. Also, current smokers or ex-smokers were excluded.
All participants were subjected to the following after writ-
ten consents:
(1) Full medical history and clinical examination.
(2) Skin prick test.
Epicutaneous prick method using standard allergen extracts
(mite, mould, grass, mixed pollens and house dust) negative
control (saline) and positive control (histamine).
All allergen extracts were prepared in Ain-Shams allergy
and Immunology Extract unit by aqueous vaccine method
(weight/volume) method (1/10 dilution) according to Neuman
and Arman 1988 [19] positive skin test was deﬁned as a wheal
3 mm in diameter greater than the wheal of negative control.
(3) Serum total immunoglobulin E (IgE): in Iu/L by ELISA.
Quantitive measurement by a commercially available ELI-
SA kit. (Med Biotech, Inc., Agenzme company, Industrial
Road, San Carlos, CA, USA).
(4) Peak expiratory ﬂow rate (PEFR):
Using traditional peak Flow meter. Results were expressed
as percentage of the predicted values considering the height,
age and sex.
(5) Sputum induction and measurement of both MMP-9
and TIMP-1 (by ELISA technique from oncogen TM
researches products, sandwich enzyme) Result were
expressed in ng/ml [20].
Sputum induction
According to Kanazawa [21] and his colleagues, patients were
premedicated with inhaled salbutamol, after washing their
mouths, they inhale normal saline by nebulizer and encour-
aged to cough deeply after 5 and 10 min into polypropylene
containers.
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The descriptive statistics (mea, standard deviation, minimum
and maximum values) for all groups were calculated. Wilcoxon
rank-sum test was used for two groups. Spearman’s rank anal-
ysis used to evaluated the correlation between data.
Results
 Group A: (stable asthmatics) showed high signiﬁcant
increase in IgE, PEFR, MMP-9, TIMP-1 and MMP-9/
TIMP-1 ratio when compared to control group ‘‘C’’
(P< 0.001) (Table 1).
 Group B: (asthmatic patients during exacerbation) showed
high signiﬁcant increase in IgE, PEFR, MMP-9, TIMP-1
and MMP-9/TIMP-1 ratio when compared to control
group ‘‘C’’ (P< 0.001) (Table 2).
 Group A: (stable asthmatic) showed high signiﬁcant increase
in IgE, MMp-9 and MMP-9/TIMP-1 ratio when compared
to group B (asthmatic during exacerbation) (P< 0.01),
(P< 0.001), (P< 0.001) respectively. PEFR showed much
reduction (P< 0.001). TIMP did not show signiﬁcant
change during exacerbation (Table 3).Table 1 Comparison between group (A) (stable asthma) and group
Parameter Group A Group C
Age (years) 34.9 ± 10.5 32.2 ± 10.
PEFR% 79.2 ± 7.7 103 ± 8.4
IgE: IU/L 483 ± 263 86 ± 27.
MMP-9 (ng/mL) 166 ± 85.3 27.4 ± 9.3
TIMP (ng/mL) 339 ± 137 129 ± 59.
Ratio 0.48 ± 0.09 0.24 ± 0.1
Table 2 Comparison between group (B) (asthma exacerbation) and
Parameter Group B Group C
Age (years) 33.6 ± 10.4 32.2 ± 10.
PEFR% 62.6 ± 7.5 103 ± 8.4
IgE: IU/L 759 ± 369 86.8 ± 27.
MMP-9 (ng/mL) 311 ± 115 27.4 ± 9.3
TIMP (ng/mL) 381 ± 109 129 ± 59.
Ratio 0.79 ± 0.15 0.24 ± 0.1
Table 3 Comparison between group (A) and group (B).
Parameter Group A Group B
Age (years) 34.9 ± 10.5 33.6 ± 10.
PEFR% 79.2 ± 7.7 62.6 ± 7.5
IgE: IU/L 483 ± 263 759 ± 369
MMP-9 (ng/mL) 166 ± 85.3 311 ± 115
TIMP (ng/mL) 339 ± 137 381 ± 109
Ratio 0.48 ± 0.09 0.79 ± 0.1 Among the patients of group A, there was negative signiﬁ-
cant correlation between PEFR and MMP-9, TIMP-1 and
MMP-9/TIMP-1 ratio. (Table 4).
 Among the patients of group B, there was negative signiﬁ-
cant correlation between PEFR andMMP-9, TIMP-1 and
MMP-9/TIMP-1 ratio (Table 5).
Discussion
Airway remolding is a major change responsible for irrevers-
ible asthmatic air ﬂow restriction [6]. MMP-9 and TIMP-1
are thought to be deeply involved in the pathogenesis of
chronic airway disease [14]. Upregulation of MMP-9 has been
previously reported in airways with chronic inﬂammation and
remodeling such as chronic obstructive pulmonary disease
including emphysema, pulmonary ﬁbrosis [22,23]. Although
the mechanism is still under investigation and not accurately
known, the imbalance between MMP-9 and TIMP-1 is consid-
ered a major theory to explain the progression of asthmatic
airway remodeling [6].
Results of the present work showed that asthmatic patients
had increased levels of MMP-9 and TIMP-1. It is increasingly
accepted that airway inﬂammation and remodeling which oc-(C) (control group).
Z P Sig
3 0.673 >0.05 NS
4.968 <0.001 HS
5 4.966 <0.001 HS
4.848 <0.001 HS
8 4.261 <0.001 HS
4 4.347 <0.001 HS
group (C) control group.
Z P Sig
3 0.397 >0.05 NS
4.908 <0.001 HS
5 4.966 <0.001 HS
4.968 <0.001 HS
8 4.848 <0.001 HS
4 4.813 <0.001 HS
Z P Sig
4 0.332 >0.05 NS
4.477 <0.001 HS
2.405 <0.001 HS
3.512 <0.001 HS
0.270 >0.05 NS
5 4.619 <0.001 HS
Table 4 Correlation between MMP-9, TIMP and ratio and all studied parameters among group ‘‘A’’.
Parameter R
MMP-9 Sig TIMP-1 Sig Ratio Sig
TIMP-1 +0.7539 +Sig
Ratio +0.51694 +Sig +0.34685 +NS
Age +0.11858 +NS +11051 +NS 0.18579 NS
PEFR 0.6313 Sig 0.66548 Sig 0.7534 Sig
IgE +0.14904 +NS +0.15990 +Ns 0.07580 NS
Table 5 Correlation between MMP-9, TIMP and ratio and all studied parameters among group ‘‘B’’.
Parameter R
MMP-9 Sig TIMP-1 Sig Ratio Sig
TIMP-1 +0.91912 +Sig
Ratio +0.7414 +Sig +0.37620 +NS
Age 0.03548 NS 0.06826 NS +0.03953 +NS
PEFR 0.64501 Sig 0.56817 Sig 0.42132 Sig
IgE +0.15913 +NS +0.05741 +Ns +0.20168 +NS
38 G.M. Mohamed et al.cur in asthma can cause functional alteration because of quan-
titative changes in airway wall compartments or by changes in
the biochemical composition of the various constituents of the
airway wall [24]. This goes with a previous workers who sug-
gested the involvement of MMP-9 in the airway remodeling
process in asthma. Upregulated expression of MMPs are
thought to mainly contribute to the abnormal degradation of
ECM in the airways, which lead to the physiological structural
changes of the airways and is also thought to be one of the
main reasons of airway hyper responsiveness [25].
The current work denoted that TIMP-1 level was signiﬁ-
cantly higher in asthmatics when compared to control. This
supported the results of previous work which suggested that
the increased level of TIMP-1 in asthmatic patients may repre-
sent an endogenous protective mechanism to down regulate
the proteolytic activity of MMPs in the lung parenchyma. In-
creased concentration of TIMP-1 in asthma can be the result
of several mediators released during development of airway
inﬂammation as transforming growth factor-B [26]. Our study
showed increased MMP-9/TIMP-1 ratio in asthmatics. This
results supported by results of previous workers who attrib-
uted this high ratio to predominance of inﬂammation over
ﬁbrosis [22,27]. Moreover, another work reported low MMP-
9/TIMP-1 ratio in sever asthmatics with poor response to ste-
roids due to excessive ﬁbrosis [20].
The results presented in our study demonstrated signiﬁcant
increase in MMP-9 but no signiﬁcant change in TIMP-1 in
asthmatics during exacerbation when compared to stable asth-
matics. These results were in agreement with another worker
who found that asthma exacerbation promote airway remodel-
ing by altering MMP-9 mediated ECM homeostasis [28]. It
was reported that levels of MMP-9 not TIMP-1 increase after
inhaled allergen challenge in sputum of allergic asthmatic pa-
tients [29].
Our results revealed signiﬁcant negative correlation be-
tween MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio with
PEFR. i.e. more airway obstraction was accompanied by more
release of MMP-9 and TIMP-1. This goes with a previouswork which showed that depletion of MMP-9 also attenuated
the peribronchial ﬁbrosis and airway hyper-responsiveness in-
duced by chronic antigen exposure [30].
Also we found that there was no signiﬁcant correlation be-
tween MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio and age
and IgE. These results disagree with previous workers who
suggested that IgE trigger reactions to inhaled allergens lead-
ing to allergic inﬂammation and release of MMP-9 [31]. The
lack of correlation to IgE in the present study may be because
acute exacerbation is due to multi-factors including allergen
exposure.
Conclusion
Our results suggested that the processes of airway inﬂamma-
tion and remodeling are coordinated, and MMP-9 and
TIMP-1 are cooperative in these pathophysiological changes
of allergic airway disease. These ﬁndings might provide a bet-
ter understanding of the regulation of airway inﬂammation
and remodeling in allergic airway disease. MMP-9 may be a
potential target for management of exacerbation of asthma
and prevention of subsequent airway remodeling.
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